In SARCs, the HDAC inhibitors showed multiple tumor inhibitory effects that included upregulating tumor suppressor genes, downregulating oncogenes, promoting apoptosis (Su et al., 2010) and cell cycle arrest (Sakimura et al., 2005), decreasing invasion, metastasis and angiogenesis (Ailenberg and Silverman, 2003; Lee et al., 2015), inducing reactive oxygen species (ROS) production (Laporte et al., 2017), autophagy (Yamamoto et al., 2008), and cell differentiation (Di Pompo et al., 2015). This evidence concerns the gene HDAC9 and neoplasm.